BiTACs benefit from novel architecture with combinatorial-gated design for cancer targeting and built-in safety features
Board adds profound clinical expertise in oncology as well as expertise across multiple antibody-based therapeutic modalities to VERAXA
New IP combined with VERAXA’s deep ADC and antibody expertise to give rise to new therapeutic strategies with unique safety features
The addition of a clinical-stage FLT3-targeting cancer antibody program acts as steppingstone for further pipeline and technology expansion.
The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.
Lars Hufnagel will be responsible for advancing VERAXA’s antibody screening and ADC technologies by further developing its droplet-based microfluidic screening technology.
